GlassScriptPhysician profile
Raymond C Tan
NPI 1104809946
$1,360.78
in general payments reported to CMS, 2019-2025
27 companies · $207 in 2025
The $207 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.78 · 2020: $32.44 · 2021: $16.36 · 2022: $228 · 2023: $312 · 2024: $541 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $322.05 | 2024-2025 | Enhertu, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $193.88 | 2020-2022 | |
| Boston Scientific Corporation | $100.70 | 2023-2025 | Spaceoar Vue System - 10ml |
| Bayer Healthcare Pharmaceuticals INC. | $61.41 | 2023-2024 | |
| Stemline Therapeutics INC. | $59.17 | 2023 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $53.34 | 2023-2024 | Libtayo |
| Sumitomo Pharma America, INC. | $51.12 | 2023-2024 | Orgovyx |
| Novocure INC. | $50.90 | 2022-2025 | Optune Gio |
| Exelixis INC. | $42.22 | 2023-2024 | Cabometyx |
| Janssen Biotech, INC. | $39.78 | 2022-2024 | Imbruvica, Talvey, Tecvayli |
| Sobi, INC | $33.23 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $28.57 | 2025 | Abilify Maintena, Abilify Asimtufii |
| Merck Sharp & Dohme LLC | $27.66 | 2023 | Lynparza, Keytruda |
| Pfizer INC. | $25.19 | 2024 | |
| Siemens Medical Solutions USA, INC. | $24.14 | 2023 | Eclipse Treatment Planning System For External Beam Radiation Therapy, Aria Radiation Therapy Management Software |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $24.10 | 2024 | Epkinly |
| Abbvie INC. | $23.83 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.78 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.72 | 2023 | Gilotrif |
| Novartis Pharmaceuticals Corporation | $23.00 | 2023 | |
| Progenics Pharmaceuticals, INC. | $20.98 | 2024 | |
| Myriad Genetic Laboratories, INC. | $20.77 | 2024 | Myrisk |
| Eisai INC. | $20.01 | 2024 | |
| Hologic Sales and Service, LLC | $19.78 | 2024 | Biozorb |
| Palette Life Sciences, INC. | $16.36 | 2021 | |
| Amgen INC. | $15.75 | 2023 | Lumakras |
| Glaxosmithkline, LLC. | $15.34 | 2023 | Ojjaara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.